Alik S. Widge

Alik S. Widge

Auto-generated profile, based on publicly available information

Alik S. Widge

University of Minnesota

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2018 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
MVMai-Anh T. Vu
Mai-Anh T. Vu
TATülay Adali
Tülay Adali
DBDemba Ba
Demba Ba
GBGyörgy Buzsáki
György Buzsáki
DCDavid Carlson
David Carlson
KDKafui Dzirasa
Kafui Dzirasa
With ever-increasing advancements in technology, neuroscientists are able to collect data in greater volumes and with finer resolution. The bottleneck in understanding how the brain works is consequently shifting away from the amount and type of data we can collect and toward what we actually do with the data. There has been a growing interest in leveraging this vast volume of data across levels of analysis, measurement techniques, and experimental paradigms to gain more insight into brain function. Such efforts are visible at an international scale, with the emergence of big data neuroscience initiatives, such as the BRAIN initiative (Bargmann et al., 2014), the Human Brain Project, the Human Connectome Project, and the National Institute of Mental Health's Research Domain Criteria initiative. With these large-scale projects, much thought has been given to data-sharing across groups (Poldrack and Gorgolewski, 2014; Sejnowski et al., 2014); however, even with such data-sharing initiatives, funding mechanisms, and infrastructure, there still exists the challenge of how to cohesively integrate all the data. At multiple stages and levels of neuroscience investigation, machine learning holds great promise as an addition to the arsenal of analysis tools for discovering how the brain works.

4 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
AWA. S. Widge
A. S. Widge
SZS. Zorowitz
S. Zorowitz
IBI. Basu
I. Basu
APA. C. Paulk
A. C. Paulk
SCS. S. Cash
S. S. Cash
DDD. D. Dougherty
D. D. Dougherty
Deep brain stimulation (DBS) is a circuit-oriented treatment for mental disorders. Unfortunately, even well-conducted psychiatric DBS clinical trials have yielded inconsistent symptom relief, in part because DBS’ mechanism(s) of action are unclear. One clue to those mechanisms may lie in the efficacy of ventral internal capsule/ventral striatum (VCVS) DBS in both major depression (MDD) and obsessive-compulsive disorder (OCD). MDD and OCD both involve deficits in cognitive control. Cognitive control depends on prefrontal cortex (PFC) regions that project into the VCVS. Here, we show that VCVS DBS’ effect is explained in part by enhancement of PFC-driven cognitive control. DBS improves human subjects’ performance on a cognitive control task and increases theta (5–8Hz) oscillations in both medial and lateral PFC. The theta increase predicts subjects’ clinical outcomes. Our results suggest a possible mechanistic approach to DBS therapy, based on tuning stimulation to optimize these neurophysiologic phenomena.

21 March 2018 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
AWAlik S. Widge
Alik S. Widge
DMDonald A. Malone
Donald A. Malone
DDDarin D. Dougherty
Darin D. Dougherty
Major depressive episodes are the largest cause of psychiatric disability, and can often resist treatment with medication and psychotherapy. Advances in the understanding of the neural circuit basis of depression, combined with the success of deep brain stimulation (DBS) in movement disorders, spurred several groups to test DBS for treatment-resistant depression. Multiple brain sites have now been stimulated in open-label and blinded studies. Initial open-label results were dramatic, but follow-on controlled/blinded clinical trials produced inconsistent results, with both successes and failures to meet endpoints. Data from follow-on studies suggest that this is because DBS in these trials was not targeted to achieve physiologic responses. We review these results within a technology-lifecycle framework, in which these early trial “failures” are a natural consequence of over-enthusiasm for an immature technology. That framework predicts that from this “valley of disillusionment,” DBS may be nearing a “slope of enlightenment.” Specifically, by combining recent mechanistic insights and the maturing technology of brain-computer interfaces (BCI), the next generation of trials will be better able to target pathophysiology. Key to that will be the development of closed-loop systems that semi-autonomously alter stimulation strategies based on a patient's individual phenotype. Such next-generation DBS approaches hold great promise for improving psychiatric care.

30 October 2015 in Brain Imaging and Behavior
Verified
Journal Article
Closed access
PDF file
NMNikos Makris
Nikos Makris
YRYogesh Rathi
Yogesh Rathi
PMPalig Mouradian
Palig Mouradian
GBGiorgio Bonmassar
Giorgio Bonmassar
GPGeorge Papadimitriou
George Papadimitriou
DDDarin D. Dougherty
Darin D. Dougherty

1 January 2017 in Experimental Neurology
Verified
Journal Article
Closed access
AWAlik S. Widge
Alik S. Widge
KEKristen K. Ellard
Kristen K. Ellard
APAngelique C. Paulk
Angelique C. Paulk
IBIshita Basu
Ishita Basu
AYAli Yousefi
Ali Yousefi
EEEmad N. Eskandar
Emad N. Eskandar

10 February 2017 in International Review of Psychiatry
Verified
Journal Article
Closed access
MLMeng-Chen Lo
Meng-Chen Lo
AWAlik S. Widge
Alik S. Widge
Despite deep brain stimulation’s positive early results in psychiatric disorders, well-designed clinical trials have yielded inconsistent clinical outcomes. One path to more reliable benefit is closed-loop therapy: stimulation that is automatically adjusted by a device or algorithm in response to changes in the patient’s electrical brain activity. These interventions may provide more precise and patient-specific treatments. This article first introduces the available closed-loop neuromodulation platforms, which have shown clinical efficacy in epilepsy and strong early results in movement disorders. It discusses the strengths and limitations of these devices in the context of psychiatric illness. It then describes emerging technologies to address these limitations, including pre-clinical developments such as wireless deep neurostimulation and genetically targeted neuromodulation. Finally, ongoing challenges and limitations for closed-loop psychiatric brain stimulation development, most notably the difficulty of identifying meaningful biomarkers for titration, are discussed. This is considered in the recently-released Research Domain Criteria (RDoC) framework, and how neuromodulation and RDoC are jointly very well suited to address the problem of treatment-resistant illness is described.